The choice isn't that hard.

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Both companies now aim to win in the oral weight loss drug market.

The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli ...

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...